Free Trial
NASDAQ:RLAY

Relay Therapeutics Q3 2023 Earnings Report

Relay Therapeutics logo
$4.62 -0.05 (-0.97%)
As of 01:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Relay Therapeutics EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.29
One Year Ago EPS
N/A

Relay Therapeutics Revenue Results

Actual Revenue
$25.20 million
Expected Revenue
$0.78 million
Beat/Miss
Beat by +$24.42 million
YoY Revenue Growth
N/A

Relay Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 2, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Relay Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Relay Therapeutics Earnings Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
Relay Therapeutics (RLAY) Receives a Buy from Guggenheim
Guggenheim Gives Buy Rating to Relay Therapeutics (RLAY)
See More Relay Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email.

About Relay Therapeutics

Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening. This approach enables Relay to explore conformational changes in proteins that have historically been difficult to target, opening new avenues for therapeutic intervention. Relay’s pipeline comprises multiple preclinical and clinical programs aimed at oncogenic drivers implicated in a range of solid tumors.

Relay Therapeutics has progressed a number of assets into human trials, with initial studies evaluating safety, tolerability and preliminary signs of clinical activity. In addition to its internal development programs, the company collaborates with academic institutions and other biopharmaceutical companies to expand the application of its platform across diverse therapeutic areas. Relay’s research efforts are supported by partnerships that bring complementary expertise and resources to accelerate the identification of novel drug candidates.

Under the leadership of President and Chief Executive Officer Michael Gilman, Ph.D., Relay Therapeutics continues to advance its vision of precision oncology medicines that address unmet medical needs. The company’s operations are primarily based in the United States, while its clinical trials enroll patients across North America and select international sites. Relay Therapeutics is publicly traded on the Nasdaq under the ticker symbol RLAY.

View Relay Therapeutics Profile

More Earnings Resources from MarketBeat